[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
Breast cancer in Brazil: present status and future goals
BL Lee, PER Liedke, CH Barrios, SD Simon… - The lancet …, 2012 - thelancet.com
Breast cancer is the most common cancer in women worldwide and 70% of breast cancer
deaths occur in women from low-income and middle-income countries. Latin America has …
deaths occur in women from low-income and middle-income countries. Latin America has …
[HTML][HTML] Optical slot-waveguide based biochemical sensors
CA Barrios - sensors, 2009 - mdpi.com
Slot-waveguides allow light to be guided and strongly confined inside a nanometer-scale
region of low refractive index. Thus stronger light-analyte interaction can be obtained as …
region of low refractive index. Thus stronger light-analyte interaction can be obtained as …
[HTML][HTML] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart, M Procter… - … England Journal of …, 2005 - Mass Medical Soc
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy …
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy …
[HTML][HTML] Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho… - The Lancet, 2019 - thelancet.com
Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
Background Pembrolizumab monotherapy showed durable antitumour activity and
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …
manageable safety in patients with metastatic triple-negative breast cancer. We aimed to …
[HTML][HTML] Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
Background The efficacy and safety of nivolumab plus cabozantinib as compared with those
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
CN Sternberg, ID Davis, J Mardiak… - Journal of clinical …, 2010 - s-space.snu.ac.kr
Purpose Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth
factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double …
factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double …
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
…, MC Dols, DL Cortinovis, J Leach, J Polikoff, C Barrios… - The Lancet, 2017 - thelancet.com
Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1)
monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and …
monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and …